Taiho Pharmaceutical

Subsidiary of Otsuka Holdings (4578)

Assets

(7 total)
7Total Assets
1Approved
5Phase 3 / Filed
1Phase 1–2 / Early
6Diseases
Quick filter:
Showing 7 of 7 assets
Target & Modality
Approved
FGFR (FGFR1/2/3/4)Small molecule
Biliary Tract Cancer
Cholangiocarcinoma
Phase 3
HIF-2alphaSmall molecule
Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Phase 3
METSmall molecule
Non-Small Cell Lung Cancer
Phase 3
CD73 (NT5E)Small molecule
Pancreatic Ductal Adenocarcinoma
Phase 3
Thymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil)Small molecule
Non-Small Cell Lung CancerColorectal CancerGastric Cancer
Phase 3
EGFRSmall molecule
Non-Small Cell Lung Cancer
Phase 1/2
RETSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
QuemliclustatPhase 2Advanced Non-Small Cell Lung Cancer
Est. primary completion 2027-12 · NCT05676931 · CT.gov ↗
What to watch
2028 (1)
April 2028 (1)
CasdatifanPhase 3Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Est. primary completion 2028-04 · NCT07011719 · CT.gov ↗
What to watch
2030 (3)
March 2030 (1)
VepafestinibPhase 1/2RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors
Est. primary completion 2030-03 · NCT04683250 · CT.gov ↗
What to watch
April 2030 (1)
Futibatinib (Lytgobi)Phase 3Biliary Tract Cancer
Est. primary completion 2030-04-30 · NCT07710885 · CT.gov ↗
What to watch
November 2030 (1)
QuemliclustatPhase 3Metastatic Pancreatic Ductal Adenocarcinoma
Est. primary completion 2030-11-30 · NCT06608927 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

27 February 2027FDA action dateZipalertinibPDUFA target action date for zipalertinib NDA
US, FDA · FDA · Source ↗

Recent

12 November 2026Filing submittedZipalertinibTaiho completes the NDA for zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion NSCLC
US, FDA · Source ↗
12 August 2026Topline resultZipalertinibREZILIENT3 Phase 3 (NCT05973773): primary endpoint met
Cullinan Therapeutics and Taiho Oncology · Source ↗
28 April 2026Filing acceptedZipalertinibFDA accepts NDA for zipalertinib (previously treated EGFR ex20ins NSCLC)
US, FDA · Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics · Source ↗
28 January 2025Topline resultZipalertinibREZILIENT1 Phase 2b primary endpoint met

Financial reports

No financial reports recorded.